Sort
4,870 grants matching “glp 1”
Arylsulfonamides for the Treatment of Primary and Metastatic Uveal Melanoma
$1,024,999Margaret Kenny Offermann · Oncospherix, Inc. · R44 · FY2023 · CA
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
$1,024,986Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2024 · AI
Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV
$1,024,945David W Scott · Inhalon Biopharma, Inc. · R44 · FY2025 · AI
IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection
$1,024,942Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2024 · AI
Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV
$1,024,926Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2024 · AI
IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection
$1,024,879Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI
Long-acting injectable tacrolimus for chronic immunosuppression
$1,024,014Thomas J. Smith · Auritec Pharmaceuticals, Inc. · R44 · FY2022 · AI
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
$1,023,875Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI
Long-acting injectable tacrolimus for chronic immunosuppression
$1,023,600Thomas J. Smith · Auritec Pharmaceuticals, Inc. · R44 · FY2023 · AI
Host Directed Orynotide for MDR Gram Negative Bacterial Infections
$1,023,350Justin Blaine Schaal · University Of Southern California · R01 · FY2025 · AI
IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus
$1,023,232Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2022 · AI
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development
$1,023,231Rajesh Krishnan · Oncternal Therapeutics, Inc. · R44 · FY2022 · CA
Retinal Gene Therapy
$1,022,735Peter Colosi · National Eye Institute · ZIA · FY2012 · EY
Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer
$1,022,522Vidya P Ramamurthy · Isoprene Pharmaceuticals, Inc. · R44 · FY2025 · CA
MolecularCellular Regulation of Hematopoiesis
$1,020,550Jonathan R Keller · Division Of Basic Sciences - Nci · ZIA · FY2012 · CA
Oral Immunotherapy with IgA to Treat C. difficile Infection
$1,020,531Michael R Simon · Secretory Iga, Inc. · R44 · FY2023 · DK
A New Small-Molecule Kinase Inhibitor for Airway Disease
$1,019,816Kay O Broschat · Nupeak Therapeutics, Inc. · R42 · FY2025 · HL
Preclinical Development of ACXT-3102 for the Treatment of Pancreatic Adenocarcinoma (PDAC)
$1,019,186Bradley T. Keller · Accuronix Therapeutics, Inc. · R42 · FY2022 · CA
Neuroprotective role of GLP-1 receptor agonists
$1,019,063Nigel H. Greig · National Institute On Aging · ZIA · FY2020 · AG
IND-enabling development for IN-002, an inhaled muco-trapping mAb against respiratory syncytial virus
$1,018,961Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2023 · AI
A Pan-Dengue Virus Immunotherapeutic for Prevention and Treatment
$1,018,661Leslie S Johnson · Macrogenics, Inc. · R01 · FY2010 · AI
Novel targeted Chemotherapeutics for Gliobastoma
$1,018,590Kerry Jean Koller · Quadriga Biosciences, Inc. · R44 · FY2017 · CA
A New Small-Molecule Kinase Inhibitor for Airway Disease
$1,018,383Kay O Broschat · Nupeak Therapeutics, Inc. · R42 · FY2024 · HL
Development of Novel Therapeutic Agents for Norovirus Infection
$1,017,777Kyeong-Ok Chang · Kansas State University · U01 · FY2009 · AI
Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma
$1,015,871Frank W. Marcoux · Leukogene Therapeutics, Inc. · R42 · FY2019 · CA